In line with this, an antiproliferative action of CB1 antagonism in thyroid, mantle cell lymphoma, colon and breast cancers [15–20], as well as in adipocyte and in hepatic myofibroblast has been demonstrated [28–31]. Here, CNR1 is linked to mantle cell lymphoma.